A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. [electronic resource]
Producer: 20170905Description: 1146-56 p. digitalISSN:- 1523-5866
- Antineoplastic Agents, Alkylating -- adverse effects
- Brain Neoplasms -- drug therapy
- Disease-Free Survival
- Drug Therapy, Combination -- adverse effects
- Female
- Glioblastoma -- drug therapy
- Humans
- Kaplan-Meier Estimate
- Lomustine -- adverse effects
- Male
- Middle Aged
- Pyrazoles -- adverse effects
- Quinolines -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.